title: Dasatinib maintenance therapy after allogeneic hematopoietic stem cell transplantation for an isolated central nervous system blast crisis in chronic myelogenous leukemia.
abstract: A 22-year-old male with Ph-positive chronic myelogenous leukemia (CML) was started on treatment with imatinib. After 12 months of therapy, he achieved a complete cytogenetic response (CCyR). Although the CCyR persisted in his bone marrow, he developed an isolated CML blast crisis in his central nervous system (CNS) after 29 months of therapy. He underwent allogeneic hematopoietic stem cell transplantation (HSCT) following combination therapy with dasatinib, intrathecal chemotherapy and cranial irradiation. Subsequently, 168 days after allogeneic HSCT, he was started on dasatinib maintenance therapy to prevent a CNS relapse. Thirty-eight months after allogeneic HSCT, he has sustained a complete molecular response in both bone marrow and CNS. We believe dasatinib has the potential to prevent CNS relapse if used for maintenance therapy after allogeneic HSCT.
authors.affiliation: Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
authors.forename: Mitsutaka
authors.initials: M
authors.lastname: Nishimoto
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Nakamae
authors.forename: Ki-Ryang
authors.initials: KR
authors.lastname: Koh
authors.forename: Saori
authors.initials: S
authors.lastname: Kosaka
authors.forename: Kana
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Morita
authors.forename: Hideo
authors.initials: H
authors.lastname: Koh
authors.forename: Takahiko
authors.initials: T
authors.lastname: Nakane
authors.forename: Masahiko
authors.initials: M
authors.lastname: Ohsawa
authors.forename: Masayuki
authors.initials: M
authors.lastname: Hino
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001752:Blast Crisis / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D001853:Bone Marrow / Q000473:pathology; D001921:Brain / Q000473:pathology; D016543:Central Nervous System Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D000069439:Dasatinib; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008297:Male; D011743:Pyrimidines / Q000627:therapeutic use*; D011859:Radiography; D012008:Recurrence; D013844:Thiazoles / Q000627:therapeutic use*; D014184:Transplantation, Homologous; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib